Drug intelligence / Profile preview

MDX-302

Development stage: Preclinical
Lead developer: VesiCURE Therapeutics

Overview

MDX-302 is a preclinical-stage drug candidate developed by VesiCURE Therapeutics. It is being investigated for the treatment of lung diseases, with its primary therapeutic area listed as respiratory diseases. The specific mechanism of action, molecular target(s), and modality have not been disclosed in public sources as of June 2025. No information on formulation, combination status, or detailed pharmacological properties is available at this time[1][2].

Beyond the preview

Go deeper on MDX-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX-302.

Explore the full profile